docking protein 5Genealiases: C20orf180 · IRS-6 · IRS6
Q-omics provides the consensus-scored DOK5 profile across patient tissues and cancer cell-line models. DOK5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DOK5 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, DOK5 RNA expression shows 18,774 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUAD, and LSCC as cancer lineages where DOK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOK5 survival associations across molecular data types. DOK5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOK5 RNA expression–survival associations across cancer types. High DOK5 expression shows unfavorable associations in UVM, UCEC, SCLC and STAD, but favorable associations in ACC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DOK5 RNA expression.
This table summarizes DOK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DOK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOK5 shows lower tumor expression in KIRC, KICH, THCA, UCEC and BRCA and higher tumor expression in LUAD. The LUAD box plot shows higher DOK5 RNA expression in tumor versus normal tissue (log2 FC = +1.960, t-test p < 0.001).
This table shows molecular features associated with DOK5 in patient tissues and cancer cell lines. In patient samples, DOK5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DOK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and OVARY.
